JPRN-UMIN000004680招募中2 期
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients - A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients
Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine0 个研究点目标入组 27 人开始时间: 2010年12月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis. 2) Patients with massive pleural or pericardial effusion,or ascites. 3) Patients with active severe infections. 4) Cases with past history of administration of HER related agents(gefitinib,trastuzumab,lapatinib,cetuximab). 5) Impossible cases with oral administration. 6) Patients with active opthalmological disease. 7) Pregnancy or lactation. 8) Patients with symptomatic brain metastasis. 9) Patients with active concomitant malignancy. 10) Patients with uncontrollabe diabetes mellitus. 11) Patients with uncontrollable complications. 12) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
已完成
2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30
已完成
2 期
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32
已完成
2 期
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43